Tirzepatide is no exception, and compounded versions may carry additional considerations compared to the FDA-approved product
Great newsstudents can access a free version of Pharmacists Letter
PubMed Lincoff AM, Brown-Frandsen K, Colhoun HM, et al
A RECENT study has identified a potential link between the use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), and an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes (T2D) or those who are overweight or obese
Real-world evidence suggests favorable cardiovascular effects, with some retrospective analyses showing tirzepatide may reduce major cardiovascular events by approximately 14% compared to semaglutide
Additionally, if you have a history of pancreatitis or have severe gastrointestinal disease, Semaglutide may be unsuitable for you